Skip to content

Pregnancy and Use of Psychoactive Substances: The Influence of Representations of Care on Care.

Pregnancy and Use of Psychoactive Substances: The Influence of Representations of Care on Care.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03567070
Acronym
ADDGEST
Enrollment
9
Registered
2018-06-25
Start date
2017-03-17
Completion date
2018-06-12
Last updated
2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Brief summary

It is observed that pregnant women using psychoactive substance (s) have a more random and more accidental pregnancy follow-up than women with no addictive problems. The consumption approach can be either omitted during the pregnancy monitoring, or entrusted to the course or more often in late pregnancy or occurs more brutally during delivery at the time of complications (neonatal or obstetric). In this context, health professionals are looking for levers that allow women to take appropriate care quickly. This difficulty of access to care questions us and all the more because the time of the pregnancy is a moment of important psychic reorganization conducive to modify its habits, to change its glance on its consumptions and thus to start a care concerning addiction. Invesigators hypothesize that this population has less access to medical care during pregnancy for fear of stigmatization by the health care provider. Invesigators propose a multicenter qualitative study based on individual clinical interviews to collect the testimony of women who used psychoactive substance (s) during their pregnancy. The purpose of this work is to identify ways to improve the multidisciplinary medical management of these women by focusing on the representations they can make care of.

Interventions

OTHERqualitative study based on an individual clinical interview

qualitative study based on an individual clinical interview

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Major patients * Pregnant or having given birth since \<28 days * Having used (whether declared or discovered incidentally) - regardless of the amount of psychoactive substance (s) during pregnancy: alcohol, and / or heroin or OST, and / or cannabis, and / or psychostimulants (cocaine, ecstasy, amphetamines) * Followed or not in addictology during pregnancy

Exclusion criteria

* Minor patients * Patients under legal protection (guardianship, guardianship) * Linguistic obstacle * Psychiatric pathology decompensated at the time of the meeting * Women who only used tobacco regularly during pregnancy * Women who have only regularly used psychoactive drugs and / or licit opiates (excluding prescription replacement products) during pregnancy

Design outcomes

Primary

MeasureTime frameDescription
individual clinical interviewbaselinequalitative study based on an individual clinical interview

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026